Nystagmus is a vision associated medical condition, characterized by repetitive and
uncontrolled movements of the eye. These movements often result in reduced vision and
can further affect the balance and coordination of the body. Fatigue and stress worsen the
prognosis of nystagmus. However, the exact cause for the condition is still unknown. The
major causes of nystagmus identified include congenital neurological problem or
neurological disorders developed in early childhood. Other causes of nystagmus include lack
of development of normal eye movement in early life, refractive error, for example, near-
sightedness (myopia) or astigmatism, inflammation of the inner ear, medications such as
anti-epilepsy drugs, and central nervous system diseases among others
The Global Nystagmus Market is expected to grow at a CAGR of approximately 6.2% during
the forecast period, 2017-2023.
The Nystagmus Market growth is majorly attributed to the increasing prevalence of the
genetic and eye related disorders. Moreover, increasing mental retardation and neurological
abnormalities will drive the market growth.
According to the World Health Organization (WHO), an estimated 253 million people live
with vision impairment, 36 million are blind, and 217 million have moderate to severe vision
impairment worldwide. An estimated 19 million children (below age 15) are vision impaired.
According to the WHO estimates, neurological abnormalities are responsible for 4.5%-11%
of all illnesses in the low or high-income economies. This is far higher as compared to the
number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is
expected to increase further over the coming years.
However, availability of expensive treatment and poor reimbursement policies in the
developing regions of the world are some of the factors, which may hamper the market
growth during the forecast period.
Key Players:
Global Nystagmus Market Top Vendors are Bristol-Myers Squibb Company, NUSAPURE,
ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International,
Inc., Bayer AG, Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Shire, and
Santen Pharmaceutical Co., Ltd., and others.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5441 .
Segmentation:
The nystagmus is segmented on the basis of type, diagnosis, treatment, and end-users.
Based on the type, the market is segmented into infantile, latent nystagmus, noonan
syndrome, and nystagmus blockage syndrome.
On the basis of the diagnosis, the market is segmented into CT scan, MR scan, chromosome
analysis, ultrasonography, and others.
On the basis of the treatment, the market is segmented into medications, surgical, and
others.
On the basis of the end-user, the market is segmented into hospitals & clinics, research
centers, specialty eye clinics, and others.
Regional Analysis:
The Global Nystagmus Market consists of countries namely the Americas, Europe, Asia
Pacific, and the Middle East and Africa.